JP2015512433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512433A5 JP2015512433A5 JP2015503848A JP2015503848A JP2015512433A5 JP 2015512433 A5 JP2015512433 A5 JP 2015512433A5 JP 2015503848 A JP2015503848 A JP 2015503848A JP 2015503848 A JP2015503848 A JP 2015503848A JP 2015512433 A5 JP2015512433 A5 JP 2015512433A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- weight
- disintegrant
- diluent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12163078 | 2012-04-04 | ||
| EP12163078.4 | 2012-04-04 | ||
| PCT/EP2013/056867 WO2013149987A1 (en) | 2012-04-04 | 2013-04-02 | Pharmaceutical formulations comprising ccr3 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018072309A Division JP6700332B2 (ja) | 2012-04-04 | 2018-04-04 | Ｃｃｒ３アンタゴニストを含む医薬製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512433A JP2015512433A (ja) | 2015-04-27 |
| JP2015512433A5 true JP2015512433A5 (enExample) | 2016-06-02 |
| JP6320990B2 JP6320990B2 (ja) | 2018-05-09 |
Family
ID=49292482
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503848A Active JP6320990B2 (ja) | 2012-04-04 | 2013-04-02 | Ｃｃｒ３アンタゴニストを含む医薬製剤 |
| JP2018072309A Active JP6700332B2 (ja) | 2012-04-04 | 2018-04-04 | Ｃｃｒ３アンタゴニストを含む医薬製剤 |
| JP2020080024A Pending JP2020143080A (ja) | 2012-04-04 | 2020-04-30 | Ｃｃｒ３アンタゴニストを含む医薬製剤 |
| JP2022026735A Pending JP2022081524A (ja) | 2012-04-04 | 2022-02-24 | Ｃｃｒ３アンタゴニストを含む医薬製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018072309A Active JP6700332B2 (ja) | 2012-04-04 | 2018-04-04 | Ｃｃｒ３アンタゴニストを含む医薬製剤 |
| JP2020080024A Pending JP2020143080A (ja) | 2012-04-04 | 2020-04-30 | Ｃｃｒ３アンタゴニストを含む医薬製剤 |
| JP2022026735A Pending JP2022081524A (ja) | 2012-04-04 | 2022-02-24 | Ｃｃｒ３アンタゴニストを含む医薬製剤 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10213421B2 (enExample) |
| EP (3) | EP3970693B1 (enExample) |
| JP (4) | JP6320990B2 (enExample) |
| KR (2) | KR102338465B1 (enExample) |
| CN (1) | CN104203213A (enExample) |
| AR (1) | AR090596A1 (enExample) |
| AU (1) | AU2013245028B2 (enExample) |
| BR (1) | BR112014024479A8 (enExample) |
| CA (1) | CA2869058C (enExample) |
| CL (1) | CL2014002524A1 (enExample) |
| CY (1) | CY1121137T1 (enExample) |
| DK (2) | DK2833864T3 (enExample) |
| EA (1) | EA027627B1 (enExample) |
| ES (3) | ES3044310T3 (enExample) |
| HR (1) | HRP20190069T1 (enExample) |
| HU (2) | HUE056943T2 (enExample) |
| IL (1) | IL234299A (enExample) |
| IN (1) | IN2014DN07082A (enExample) |
| LT (1) | LT2833864T (enExample) |
| MX (1) | MX358307B (enExample) |
| NZ (1) | NZ628993A (enExample) |
| PH (1) | PH12014502241A1 (enExample) |
| PL (2) | PL3524230T3 (enExample) |
| PT (2) | PT3524230T (enExample) |
| RS (1) | RS58360B1 (enExample) |
| SI (1) | SI2833864T1 (enExample) |
| SM (1) | SMT201900121T1 (enExample) |
| TR (1) | TR201821285T4 (enExample) |
| TW (1) | TW201400115A (enExample) |
| UY (1) | UY34730A (enExample) |
| WO (1) | WO2013149987A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| AR090566A1 (es) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| US11382907B2 (en) * | 2017-04-05 | 2022-07-12 | Alkahest, Inc. | Methods and compositions for treating aging-associated impairments using CCR3-inhibitors |
| EA201992356A1 (ru) * | 2017-04-05 | 2020-03-23 | Алкахест Инк. | Способ и композиция для лечения заболевания, связанного с сетчаткой глаза, с использованием ингибитора ccr3 |
| CA3076017A1 (en) * | 2017-10-13 | 2019-04-18 | Alkahest, Inc. | Methods and compositions for treating pruritus, xerosis, and associated disease using ccr3-inhibitors |
| US11426399B2 (en) | 2018-05-15 | 2022-08-30 | Alkahest, Inc. | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase |
| EP3856195A4 (en) * | 2018-09-26 | 2022-06-22 | Alkahest, Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF AGING-RELATED DISORDERS USING CCR3 INHIBITORS |
| US12692301B2 (en) | 2020-06-11 | 2026-07-28 | Alkahest Inc. | Methods of improving retina-associated disease outcome using CCR3-inhibitors |
| WO2022045226A1 (ja) | 2020-08-27 | 2022-03-03 | Ａｇｃ株式会社 | 無アルカリガラスおよびガラス板 |
| CA3221177A1 (en) | 2021-11-01 | 2023-05-04 | Meghan Kerrisk Campbell | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7907121L (sv) | 1979-08-27 | 1981-02-28 | Astra Laekemedel Ab | Ftalimidinderivat |
| US4992277A (en) | 1989-08-25 | 1991-02-12 | Schering Corporation | Immediate release diltiazem formulation |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| IL116539A (en) * | 1995-01-06 | 2002-02-10 | Noven Pharma | Preparations given through the skin of unstable anti-acid drugs |
| WO1998050019A1 (en) * | 1997-05-09 | 1998-11-12 | Sage Pharmaceuticals, Inc. | Stable oral pharmaceutical dosage forms |
| WO1999037619A1 (en) | 1998-01-21 | 1999-07-29 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| US6140349A (en) | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| EP1052992A1 (en) | 1998-02-02 | 2000-11-22 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| SE9802973D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| US20040082788A1 (en) * | 2002-07-08 | 2004-04-29 | Chemgenex Therapeutics, Inc. | Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof |
| AU2004272607B2 (en) | 2003-09-11 | 2008-11-06 | Cornerstone Therapeutics Inc. | Monoclonal antibodies against HMGB1 |
| EP1680408A2 (en) | 2003-10-24 | 2006-07-19 | F. Hoffmann-La Roche Ag | Ccr3 receptor antagonists |
| MXPA06004626A (es) | 2003-11-17 | 2006-06-27 | Boehringer Ingelheim Int | Indoles sustituidos con piperidina o sus heteroderivados y su uso como moduladores del receptor de quemocina (ccr3). |
| EP1725235B1 (en) | 2004-02-05 | 2009-04-15 | Schering Corporation | Piperidine derivatives useful as ccr3 antagonists |
| JP2006137718A (ja) | 2004-11-12 | 2006-06-01 | Astellas Pharma Inc | インドール若しくはインダゾール誘導体 |
| WO2006083390A2 (en) | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
| DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
| JP3701964B1 (ja) | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
| WO2006117314A2 (en) | 2005-04-30 | 2006-11-09 | Boehringer Ingelheim International Gmbh | Novel piperidin- substituted indoles and their use as ccr-3 modulators |
| NL2000323C2 (nl) * | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
| CA2647448A1 (en) | 2006-04-12 | 2007-10-18 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
| WO2008049875A1 (en) | 2006-10-27 | 2008-05-02 | Boehringer Ingelheim International Gmbh | Novel substituted piperidyl-propane-thiols |
| ATE537166T1 (de) | 2006-10-27 | 2011-12-15 | Boehringer Ingelheim Int | Piperidylpropanthiole als ccr3-modulatoren |
| GB0701992D0 (en) | 2007-02-02 | 2007-03-14 | 7Tm Pharma As | Grehlin Receptor Modulators |
| US8008092B2 (en) | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
| US8530488B2 (en) | 2007-10-24 | 2013-09-10 | Generics [Uk] Limited | Crystalline forms of bosentan |
| TW201000446A (en) | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
| WO2010052727A1 (en) * | 2008-11-04 | 2010-05-14 | Ideal Cures Private Limited | High performance film coating compositions |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| EP2727908A3 (en) * | 2009-04-22 | 2014-08-20 | Axikin Pharmaceuticals, Inc. | 2,5-disubstituted arylsulfonamide CCR3 antagonists |
| KR101687144B1 (ko) | 2009-04-22 | 2016-12-15 | 액시킨 파마수티컬스 인코포레이티드 | 2,5-이치환된 아릴설폰아마이드 ｃｃｒ3 길항제 |
| EP2523654A4 (en) * | 2010-01-11 | 2014-08-06 | Mohamed Shafee Muneera | IMMEDIATE RELEASE COMPOSITIONS OF MEDICAMENTS LABILES ACIDES |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| AR090566A1 (es) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
| US20130261153A1 (en) | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
-
2013
- 2013-03-27 US US13/851,538 patent/US10213421B2/en active Active
- 2013-04-02 HR HRP20190069TT patent/HRP20190069T1/hr unknown
- 2013-04-02 DK DK13714618.9T patent/DK2833864T3/en active
- 2013-04-02 SI SI201331330T patent/SI2833864T1/sl unknown
- 2013-04-02 EP EP21190323.2A patent/EP3970693B1/en active Active
- 2013-04-02 CN CN201380016781.7A patent/CN104203213A/zh active Pending
- 2013-04-02 HU HUE18213458A patent/HUE056943T2/hu unknown
- 2013-04-02 EA EA201401082A patent/EA027627B1/ru not_active IP Right Cessation
- 2013-04-02 HU HUE13714618A patent/HUE041519T2/hu unknown
- 2013-04-02 JP JP2015503848A patent/JP6320990B2/ja active Active
- 2013-04-02 KR KR1020207021307A patent/KR102338465B1/ko active Active
- 2013-04-02 DK DK18213458.5T patent/DK3524230T3/da active
- 2013-04-02 WO PCT/EP2013/056867 patent/WO2013149987A1/en not_active Ceased
- 2013-04-02 PT PT182134585T patent/PT3524230T/pt unknown
- 2013-04-02 NZ NZ628993A patent/NZ628993A/en unknown
- 2013-04-02 RS RS20190050A patent/RS58360B1/sr unknown
- 2013-04-02 SM SM20190121T patent/SMT201900121T1/it unknown
- 2013-04-02 BR BR112014024479A patent/BR112014024479A8/pt not_active Application Discontinuation
- 2013-04-02 TR TR2018/21285T patent/TR201821285T4/tr unknown
- 2013-04-02 CA CA2869058A patent/CA2869058C/en active Active
- 2013-04-02 PL PL18213458T patent/PL3524230T3/pl unknown
- 2013-04-02 ES ES21190323T patent/ES3044310T3/es active Active
- 2013-04-02 ES ES18213458T patent/ES2898179T3/es active Active
- 2013-04-02 KR KR1020147027802A patent/KR102138709B1/ko active Active
- 2013-04-02 PT PT13714618T patent/PT2833864T/pt unknown
- 2013-04-02 EP EP13714618.9A patent/EP2833864B1/en active Active
- 2013-04-02 AU AU2013245028A patent/AU2013245028B2/en active Active
- 2013-04-02 IN IN7082DEN2014 patent/IN2014DN07082A/en unknown
- 2013-04-02 MX MX2014011787A patent/MX358307B/es active IP Right Grant
- 2013-04-02 PL PL13714618T patent/PL2833864T3/pl unknown
- 2013-04-02 ES ES13714618T patent/ES2715844T3/es active Active
- 2013-04-02 EP EP18213458.5A patent/EP3524230B1/en active Active
- 2013-04-02 LT LTEP13714618.9T patent/LT2833864T/lt unknown
- 2013-04-03 AR ARP130101093A patent/AR090596A1/es unknown
- 2013-04-03 TW TW102112244A patent/TW201400115A/zh unknown
- 2013-04-04 UY UY0001034730A patent/UY34730A/es unknown
-
2014
- 2014-08-26 IL IL234299A patent/IL234299A/en active IP Right Grant
- 2014-09-24 CL CL2014002524A patent/CL2014002524A1/es unknown
- 2014-10-03 PH PH12014502241A patent/PH12014502241A1/en unknown
-
2018
- 2018-04-04 JP JP2018072309A patent/JP6700332B2/ja active Active
- 2018-12-28 US US16/235,905 patent/US20190151300A1/en not_active Abandoned
-
2019
- 2019-01-17 CY CY20191100062T patent/CY1121137T1/el unknown
-
2020
- 2020-04-29 US US16/861,473 patent/US11612596B2/en active Active
- 2020-04-30 JP JP2020080024A patent/JP2020143080A/ja active Pending
-
2022
- 2022-02-24 JP JP2022026735A patent/JP2022081524A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6700332B2 (ja) | Ｃｃｒ３アンタゴニストを含む医薬製剤 | |
| JP2018021082A5 (enExample) | ||
| JP6487599B2 (ja) | エスシタロプラム医薬組成物 | |
| EA039006B1 (ru) | Ингибиторы тирозинкиназы | |
| TWI750143B (zh) | 含有2-{4-[n-(5,6-二苯基吡-2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物 | |
| US11331273B2 (en) | Film-coated tablet having high chemical stability of active ingredient | |
| JP2020158435A (ja) | リナグリプチン含有医薬組成物及びその製造方法、並びにリナグリプチン含有医薬組成物の品質の向上方法 | |
| KR101446129B1 (ko) | 프란루카스트-함유 고형 제제의 제조방법 | |
| JP2017031117A (ja) | 光安定性を向上した、イミダフェナシン製剤 | |
| WO2016079687A1 (en) | Oral pharmaceutical composition of teriflunomide | |
| JPWO2009123169A1 (ja) | アミド誘導体含有医薬組成物 | |
| EP1968593B1 (en) | Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid | |
| JP2016155777A (ja) | モンテルカスト又はその塩を含む組成物 | |
| WO2015069203A1 (en) | Capsule comprising rupatadine fumarate and montelukast sodium | |
| WO2011012987A1 (en) | Pharmaceutical composition of isoniazid | |
| JP6883401B2 (ja) | アジルサルタン含有錠剤及び錠剤におけるアジルサルタンの安定化方法 | |
| JP7271869B2 (ja) | レボセチリジン含有錠剤 | |
| JP2014114243A (ja) | 安定な固形製剤の製造方法 | |
| JP2020015690A (ja) | レボセチリジン含有錠剤 | |
| US12629365B2 (en) | Pharmaceutical compositions of 5-HT6 receptor antagonist | |
| WO2019132839A1 (en) | Oral pharmaceutical compositions of dabigatran | |
| JP2019073445A (ja) | アプレピタントを有効成分とする医薬組成物 | |
| JP6340270B2 (ja) | 安定なモンテルカストナトリウム含有経口固形医薬組成物、その製造方法、およびモンテルカストナトリウムの類縁物質生成抑制方法 | |
| JP6336651B1 (ja) | 化学的安定性が改善されたエソメプラゾール塩を含有する錠剤 | |
| JP2020189815A (ja) | デュロキセチン製剤およびその安定化方法 |